TrialJournal for immunotherapy of cancer2024

Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL.

Ekaterina Mikhailova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.